SUMMARY Information was collected for a large number of coronary risk factors on a series of 568 married, white men, aged 30-70 years, who died from coronary heart disease. Information on the same risk factors was collected on an equal number of living controls matched on age, sex, marital status and neighborhood. For regular aspirin users (i.e., _ 4 days per week) compared with non-users, the crude matched pair risk ratio estimate was 1.0 (95% confidence limits 0.9-1.1). Even after controlling for possible confounding effects of other variables using a paired multiple logistic regression analysis, there was no evidence of association. These data provide no evidence for a preventive role of regular aspirin intake in coronary deaths.
IN PHARMACOLOGIC STUDIES, 1,2 the finding of a reduction of platelet aggregation by aspirin has suggested its possible preventive role in coronary heart disease (CHD). However, conflicting results have been reported in epidemiologic studies of this association.3 6 In a hospital-based case-control study of non-fatal myocardial infarction (MI), the risk ratio of MI among regular aspirin users (defined as taking aspirin four or more days per week) was 0.53 that of nonusers, a finding which indicated a protective effect of regular aspirin intake upon MI. In a randomized clinical trial of aspirin therapy among survivors of MI,5 the results were not statistically significant but were compatible with a small protective effect of aspirin which increased with duration of use. In contrast, the results of a large prospective cohort study of deaths due to coronary heart disease6 indicated no association with aspirin use.
This report evaluates from retrospective data whether there is an association between regular aspirin intake and coronary deaths. The design uses male subjects who died as a result of CHD. Neighbors of these men are used as controls.
Methods

Study Population
The study population of cases and controls was restricted to married white men age 30-70 residing in two Florida counties. Subjects were identified by weekly reviews of death certificates during a 16 month period. Only men whose deaths were attributed to CHD within 24 hours after onset of symptoms were included.
One living control, individually matched as to age within the same decade (i.e., 30-39, 40-49, etc.) and neighborhood of residence, was selected for each case by a systematic household survey.
Of 1,019 wives of eligible patients, 174 were nonrespondents and an additional 196 had to be excluded due to non-cooperation. The final study population consisted of 649 case-control pairs. Of these 649 pairs, 81 were excluded because of missing or unknown values, so that the data analysis are based on 568 casecontrol pairs.
Procedures
Letters of introduction were sent to the wives of eligible patients. An interviewer telephoned the wives to obtain an interview, which was conducted in the home between two weeks to two months after the death of the patient. For each wife of a case interviewed, a wife of a control was also interviewed. The interviewer asked questions concerning the husband's aspirin consumption during the three months before death for the case Table 1 shows the results of various crude matched pair risk ratio estimates and their 95% confidence limits. For the total series of 568 case-control pairs, there were 94 in which the case was an aspirin user and the control was not, and 92 in which the control was an aspirin user and the case was not. The risk ratio estimate was, therefore, 1.0 (95% two-sided confidence limits 0.9 to 1.1).
To determine whether this result was affected by the presence or absence of prior CHD among cases, we obtained additional crude matched pair risk ratio estimates, the first among the 312 pairs without prior CHD, and the second among the 233 pairs with a prior history of CHD (23 pairs where the control had a prior history of CHD and the case had no such history were excluded). These estimates were 0.9 (0.6-1.3) and 1.3 (0.8-2.2), respectively. Table 2 shows the results of the paired multiple logistic regression analyses for the 568 pairs, specifically, the variables significantly associated with the within pair differences for aspirin intake. These variables are first, use of additives (i.e. milk, cream, non-dairy creamer) with coffee or tea, followed in order by current cigarette smoking, history of elevated Abbreviation: CHD = coronary heart disease. An additional selection occurred before admission, since about 60% of MI patients die before getting to a hospital.'1 These patients, therefore, are a highly selected subgroup of the total number of patients who experience MI. It is possible that aspirin intake is unrelated to the onset of MI, but favors survival following the event.
The controls were patients admitted to the hospitals for a variety of conditions, any of which may have had positive associations with aspirin. Aspirin may cause some conditions, such as gastrointestinal disturbances. The chronic persistence of other conditions, such as arthritis or headache, may have led some controls to take aspirin. Nevertheless, in the Jick study, subjects with a secondary diagnosis of these conditions were not excluded. This previous study, therefore, is an example of the selection bias of hospital data (Berkson's fallacy)."2 The underlying concept is that in the general population in which disease is incident, the variable "hospitalization" has the associations with exposure and outcome characteristic of a confounding variable, but it is not a confounding variable because it is an effect of exposure. It should not, therefore, be "controlled" by restriction, that is, by limiting the study to the hospitalized group.
The results of the randomized case-control study of Elwood et al.5 showed a small protective, though nonsignificant, effect of aspirin on the recurrence of MI. In the present investigation, there is no evidence of a protective effect of aspirin, even when restricting our analyses to those pairs where the case had a prior history of CHD and the control did not. This finding is compatible with the results of a clinical investigation by Frishman" et al., who found no effect of aspirin on the reduction of anginal pain during exercise.
The validity of the findings of the present study may be affected by at least two possible sources of bias, namely, selection and observation.
Selection Bias
A potential source of bias exists in the selection of wives for interview, in that the wives of patients may have been more or less available for interview than the wives of controls. Insofar as availability is associated with the husband's aspirin consumption, a systematic error in either direction could result.
It is also possible that selection bias may have oc- Observation Bias A second potential source of bias is that wives may not accurately report the aspirin intake of their husbands. This inaccuracy may have been systematically different for cases and controls, since subjects had died and controls were alive. Depending on whether wives thought that using aspirin was either unhealthy or healthy, they may have either over-or underestimated their husband's aspirin consumption. Wives of controls might have also over-or underestimated their husband's aspirin consumption. This systematic error would lead to either an under-or overestimate of the protective effect of aspirin. A systematic inaccuracy in the opposite direction could also be supposed. Since we collected information from the husbands of 48 control wives about their own aspirin intake, we were able to determine whether this potential source of bias was present among controls. The husbands and wives reported very similar frequencies of regular aspirin intake (20.8% and 18.8%, respectively). It was, of course, not possible to evaluate this potential source of bias among cases.
In summary, these findings from retrospective data provide no evidence of a protective role of regular aspirin use in coronary deaths either among patients with or without a history of CHD. To further clarify this relationship, it will be important to compare results from several investigations using different study designs. In that regard, the outcome of the ongoing Aspirin Myocardial Infarction Study (AMIS),1" a cooperative, randomized clinical trial, will be particularly informative.
